TickerTalks
Browse all tickers →
TickerTalks›$IMTX
IMIMTX

Immatics N.V.

$IMTX·$996M·Biotechnology·Healthcare
$6.83-5.3%YTD-35.0%1Y-32.3%
Price updated 13h ago·X counts updated 3d ago
IMIMTX
$IMTXImmatics N.V.
$6.83-5.27%9 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $IMTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

9X posts · last 7 days
Sep 28Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $IMTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Immatics with Anzu-Cel 1H27 catalyst plus $150M offering — the specialty-cell-therapy biotech into Nov 17.

Immatics is a clinical-stage cell-therapy biopharma whose 2026 catalyst is specific — Anzu-Cel's 1st half 2027 catalyst plus potential label expansion for uveal melanoma is the explicit forward driver, with the just-announced $150M underwritten offering anchoring the balance sheet.

  • The P&L is clinical-stage: Q2 revenue grew 93% YoY to $9.1M at a -735% operating margin and EPS of -$0.46, with trailing EPS prints missing Street estimates by 10.5% and 19.1% — these are the small-dollar misses typical of a cell-therapy biotech burning through specific pipeline funding.
  • The specific capital-markets positioning is substantive: 'Buy on Anzu-Cel 1st Half 2027 Catalyst and Potential Label Expansion for Uveal Melanoma' Seeking Alpha framing plus the $150M underwritten offering — these are coordinated signals supporting the specific 2027 catalyst setup.

At 9% of its 52-week range and 14% below the 200-day going into Nov 17 earnings, the setup is a classic cell-therapy-at-drawdown catalyst coil. A specific Anzu-Cel data update or named uveal-melanoma label-expansion commentary is the trigger; a safety signal or another large per-share-loss surprise is the invalidation.

Agrees with X sentimentThe specific 'Buy on Anzu-Cel 1st Half 2027 Catalyst' framing is grounded on a specific sell-side anchor, and the $150M offering is a specific balance-sheet-management event.

What to watch: Nov 17 Q3 earnings — Anzu-Cel data readouts, cash runway, uveal-melanoma label-expansion commentary, and FY27 guide. Clean Anzu-Cel data is the trigger; safety signal is the invalidation.

On the calendar: 2026-11-17 — Q3 earnings

event ahead 30dcell therapy

Read the AI verdict on $IMTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biopharma developing TCR-based T-cell receptor therapies for solid tumors, with major partnerships at BMS and Roche.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IMTX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $IMTX

Neutral — Clinical-stage biopharma developing TCR-based T-cell receptor therapies for solid tumors, with major partnerships at BMS and Roche.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+32.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-52.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-5.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-19.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
26.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-47.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
77.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 18, 2026$-0.53$-0.48-10.5%
Q1 2026May 12, 2026$-0.50$-0.42-19.0%
Q4 2025Mar 5, 2026$-0.34$-0.48+29.2%
Q3 2025Nov 17, 2025$-0.49$-0.44-11.5%
Next earningsTue, Nov 17·consensus EPS $-0.50

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$9.1M+93.0%100%-735%$-0.46$-62.1M
Q1 FY26$7.6M-59.0%100%-868%$-0.43$-43.5M
Q4 FY25$19.8M-64.9%100%-197%$-0.28$-58.6M
Q3 FY25$5.2M-89.7%100%-1053%$-0.42$-45.8M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$42.8M$24.5M – $62.9M-$2.03-$2.35 – -$1.735
FY27$36.0M$20.6M – $52.9M-$2.11-$2.86 – -$1.645
FY28$113.4M$15.5M – $230.4M-$1.84-$2.43 – -$1.427
FY29$231.3M$132.2M – $340.1M-$1.02-$1.64 – -$0.453
FY30$442.7M$253.0M – $651.0M-$0.15-$0.24 – -$0.075

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.1%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-22.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-30.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 112.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.365-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 26Perceptive Advisors LlcDirector863.1K sh$7.5M
+ 10 other (10 awards) in window

See when $IMTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 27SC 13D/A
AI summary

Perceptive Advisors LLC and its master fund, Perceptive Life Sciences Master Fund, Ltd., filed Amendment No. 2 to their Schedule 13D for Immatics N.V. (IMTX), disclosing beneficial ownership of 11,418,016 shares representing approximately 7.6% of the company's outstanding shares. Perceptive Advisors is a Delaware-incorporated registered investment adviser that manages the fund on behalf of its clients. The event date for this amendment is August 26, 2026.

3New insider — initial holdingsJul 293
AI summary

James Nelson Pepin, General Counsel and Corporate Secretary of Immatics N.V., filed an initial Form 3 statement of beneficial ownership with an event date of July 20, 2026. The filing reports no securities of the issuer currently owned by the reporting person. This is a standard initial disclosure required upon assuming a new officer role.

+ 14 other (8 6-Ks · 5 13Gs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrastdefenseworld.net·5d agoImmatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Whydefenseworld.net·5d agoImmatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?defenseworld.net·12d agoImmatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanomaseekingalpha.com·50d agoImmatics Announces $150 Million Underwritten Offeringglobenewswire.com·50d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $IMTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport